Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
Science
The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).